TRAW Fundamental Analysis - TRAWS PHARMA INC

Name: TRAWS PHARMA INC (TRAW) Stock
Brand: TRAWS PHARMA INC
Rating: 7 (3 reviews)

Fundamental Rating

TRAW gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. TRAW scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TRAW has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TRAW was profitable.

In the past year TRAW has reported a negative cash flow from operations.

TRAW had negative earnings in each of the past 5 years.

TRAW had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of 562.73%, TRAW belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

Looking at the Return On Equity, with a value of 1064.03%, TRAW belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	562.73%
ROE	1064.03%
ROIC	N/A

ROA(3y)-116.91%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 3028.25%, TRAW belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

The Operating Margin and Gross Margin are not available for TRAW so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	3028.25%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for TRAW has been increased compared to 1 year ago.

There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -58.24, we must say that TRAW is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -58.24, TRAW is doing worse than 92.71% of the companies in the same industry.

TRAW has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-58.24

ROIC/WACCN/A

WACC8.75%

2.3 Liquidity

A Current Ratio of 2.09 indicates that TRAW has no problem at all paying its short term obligations.

With a Current ratio value of 2.09, TRAW is not doing good in the industry: 60.42% of the companies in the same industry are doing better.

TRAW has a Quick Ratio of 2.09. This indicates that TRAW is financially healthy and has no problem in meeting its short term obligations.

TRAW's Quick ratio of 2.09 is in line compared to the rest of the industry. TRAW outperforms 45.31% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.09
Quick Ratio	2.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 114.90% over the past year.

The Revenue has grown by 1184.51% in the past year. This is a very strong growth!

EPS 1Y (TTM)114.9%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.91%

Revenue 1Y (TTM)1184.51%

Revenue growth 3Y0%

Revenue growth 5YN/A

Sales Q2Q%4694.74%

3.2 Future

The Earnings Per Share is expected to grow by 41.24% on average over the next years. This is a very strong growth

TRAW is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.21% yearly.

EPS Next Y76.99%

EPS Next 2Y41.24%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year0%

Revenue Next 2Y14.21%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 0.13 indicates a rather cheap valuation of TRAW.

TRAW's Price/Earnings ratio is rather cheap when compared to the industry. TRAW is cheaper than 99.48% of the companies in the same industry.

Compared to an average S&P500 Price/Earnings ratio of 26.89, TRAW is valued rather cheaply.

The Forward Price/Earnings Ratio is negative for TRAW. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	0.13
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

TRAW's earnings are expected to grow with 41.24% in the coming years. This may justify a more expensive valuation.

PEG (NY)0

PEG (5Y)N/A

EPS Next 2Y41.24%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TRAW!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TRAWS PHARMA INC

NASDAQ:TRAW (10/27/2025, 5:54:31 PM)

After market: 2.8 +0.2 (+7.69%)

2.6

-0.11 (-4.06%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-13 2025-08-13

Earnings (Next)11-12 2025-11-12

Inst Owners9.31%

Inst Owner Change0%

Ins Owners6.11%

Ins Owner Change0%

Market Cap18.54M

Revenue(TTM)2.90M

Net Income(TTM)87.91M

Analysts82.86

Price TargetN/A

Short Float %1.36%

Short Ratio0.45

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)2179.41%

Min Revenue beat(2)-6.86%

Max Revenue beat(2)4365.69%

Revenue beat(4)1

Avg Revenue beat(4)1088.3%

Min Revenue beat(4)-6.86%

Max Revenue beat(4)4365.69%

Revenue beat(8)1

Avg Revenue beat(8)537.82%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	0.13
Fwd PE	N/A
P/S	6.39
P/FCF	N/A
P/OCF	N/A
P/B	2.24
P/tB	2.24
EV/EBITDA	N/A

EPS(TTM)19.77

EY760.38%

EPS(NY)-0.83

Fwd EYN/A

FCF(TTM)-3.78

FCFYN/A

OCF(TTM)-3.78

OCFYN/A

SpS0.41

BVpS1.16

TBVpS1.16

PEG (NY)0

PEG (5Y)N/A

Graham Number22.7

Profitability

		Industry Rank	Sector Rank
ROA	562.73%
ROE	1064.03%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	3028.25%
GM	N/A
FCFM	N/A

ROA(3y)-116.91%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.19

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.09
Quick Ratio	2.09
Altman-Z	-58.24

F-Score6

WACC8.75%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)114.9%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.91%

EPS Next Y76.99%

EPS Next 2Y41.24%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)1184.51%

Revenue growth 3Y0%

Revenue growth 5YN/A

Sales Q2Q%4694.74%

Revenue Next Year0%

Revenue Next 2Y14.21%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y1.85%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year79.79%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-66.01%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-66.14%

OCF growth 3YN/A

OCF growth 5YN/A

TRAWS PHARMA INC / TRAW FAQ

What is the fundamental rating for TRAW stock?

ChartMill assigns a fundamental rating of 4 / 10 to TRAW.

Can you provide the valuation status for TRAWS PHARMA INC?

ChartMill assigns a valuation rating of 4 / 10 to TRAWS PHARMA INC (TRAW). This can be considered as Fairly Valued.

Can you provide the profitability details for TRAWS PHARMA INC?

TRAWS PHARMA INC (TRAW) has a profitability rating of 3 / 10.

What is the financial health of TRAWS PHARMA INC (TRAW) stock?

The financial health rating of TRAWS PHARMA INC (TRAW) is 6 / 10.

TRAWS PHARMA INC (TRAW) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TRAWS PHARMA INC / TRAW FAQ

What is the fundamental rating for TRAW stock?

Can you provide the valuation status for TRAWS PHARMA INC?

Can you provide the profitability details for TRAWS PHARMA INC?

What is the financial health of TRAWS PHARMA INC (TRAW) stock?